Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 4
2003 12
2004 7
2005 18
2006 16
2007 25
2008 21
2009 35
2010 36
2011 43
2012 44
2013 67
2014 67
2015 69
2016 57
2017 92
2018 66
2019 70
2020 66
2021 83
2022 70
2023 57
2024 30

Text availability

Article attribute

Article type

Publication date

Search Results

949 results

Results by year

Filters applied: . Clear all
Page 1
STING Mediates LPS-induced Acute Lung Injury by Regulating Ferroptosis.
Gu Y, Lv L, Jin J, Hua X, Xu Q, Wu R, Zhu S, Liu X, Lv T, Song Y, Zhang F. Gu Y, et al. Among authors: song y. Exp Cell Res. 2024 Apr 17:114039. doi: 10.1016/j.yexcr.2024.114039. Online ahead of print. Exp Cell Res. 2024. PMID: 38641125 Free article.
The β2-adrenergic receptor associates with CXCR4 multimers in human cancer cells.
Liang J, Seghiri M, Singh PK, Seo HG, Lee JY, Jo Y, Song YB, Park C, Zalicki P, Jeong JY, Huh WK, Caculitan NG, Smith AW. Liang J, et al. Among authors: song yb. Proc Natl Acad Sci U S A. 2024 Apr 2;121(14):e2304897121. doi: 10.1073/pnas.2304897121. Epub 2024 Mar 28. Proc Natl Acad Sci U S A. 2024. PMID: 38547061
Tislelizumab Plus Platinum and Etoposide Versus Placebo Plus Platinum and Etoposide as First-Line Treatment for Extensive-Stage SCLC (RATIONALE-312): A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase 3 Clinical Trial.
Cheng Y, Fan Y, Zhao Y, Huang D, Li X, Zhang P, Kang M, Yang N, Zhong D, Wang Z, Yu Y, Zhang Y, Zhao J, Qin T, Chen C, Leaw S, Zheng W, Song Y; RATIONALE-312 Study Group. Cheng Y, et al. Among authors: song y. J Thorac Oncol. 2024 Mar 7:S1556-0864(24)00115-1. doi: 10.1016/j.jtho.2024.03.008. Online ahead of print. J Thorac Oncol. 2024. PMID: 38460751 Free article.
Updated overall survival and circulating tumor DNA analysis of ensartinib for crizotinib-refractory ALK-positive NSCLC from a phase II study.
Zheng J, Wang T, Yang Y, Huang J, Feng J, Zhuang W, Chen J, Zhao J, Zhong W, Zhao Y, Zhang Y, Song Y, Hu Y, Yu Z, Gong Y, Chen Y, Ye F, Zhang S, Cao L, Fan Y, Wu G, Guo Y, Zhou C, Ma K, Fang J, Feng W, Liu Y, Zheng Z, Li G, Wang H, Cang S, Wu N, Song W, Liu X, Zhao S, Ding L, Selvaggi G, Wang Y, Xiao S, Wang Q, Shen Z, Zhou J, Zhou J, Zhang L. Zheng J, et al. Among authors: song y. Cancer Commun (Lond). 2024 Apr;44(4):455-468. doi: 10.1002/cac2.12524. Epub 2024 Feb 29. Cancer Commun (Lond). 2024. PMID: 38421881 Free PMC article. Clinical Trial.
949 results